A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.

Our group developed a subunit vaccine candidate against dengue virus based on two different viral regions: the domain III of the envelope protein and the capsid protein. The novel chimeric protein from dengue-2 virus [domain III-capsid (DIIIC-2)], when presented as aggregated incorporating oligodeoxynucleotides, induced anti-viral and neutralizing antibodies, a cellular immune response and conferred significant protection to mice and monkeys. The remaining constructs were already obtained and properly characterized.

[Detection of antirabic antibodies in personnel at risk through the use of the neutralization technique by reducing the number of plaques].

The neutralization technique by reducing the number of plaques (NRNP) for detecting antirabic antibodies in personnel at risk was used. Serum samples from individuals at high risk and from persons with vaccination antecedents and without them were studied. The neutralization technique was compared with the biological technique in mouses and as a result of the study it was obtained a concordance of 100%.